Sponsored by
Latest
Topics
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Featured
Spreadsheets
3 Hurdles of Moving on From Excel
Staffers often resist pivoting away from the popular spreadsheet platform.
By
Bob Violino
| May 25, 2022
Read More
Resources
CFO Live
Sign Up
Menu
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Explore
Search
Latest
Resources
CFO Live
Sign Up
Sponsored by
Shire
Strategy
Shire Accepts Improved $62B Bid From Takeda
The deal is the largest-ever by a Japanese company and gives Takeda a lucrative portfolio of rare disease drugs.
By
Matthew Heller
| May 8, 2018
Read More
Strategy
Ireland’s Shire Buys Baxalta for $32 Billion
The drug maker says the deal will further its goal of "building the leading biotechnology company focused on rare diseases."
By
Katie Kuehner-Hebert
| January 11, 2016
Read More
Strategy
Shire to Buy Rival Drug Maker Dyax for $5.9B
The deal gives the acquisitive Irish company access to an experimental drug that competes with its own treatment for a rare disease.
By
Matthew Heller
| November 2, 2015
Read More
Tax
Another Tax Inversion Deal in the Works
The hue and cry over tax inversions is not stopping companies from proceeding with more mergers that take advantage of the tactic.
By
Iris Dorbian
| July 28, 2014
Read More
Tax
Treasury Stance Regardless, Another Tax-Inversion Deal Pops Up
AbbVie's plans to pay less taxes by relocating to Britain after buying Shire touches a raw nerve in Washington.
By
Iris Dorbian
| July 19, 2014
Read More